Genea Biomedx and Rhea Fertility Sign MOU to Lead Innovation in Assisted Reproductive Technology

Feb. 25, 2025 - PRLog -- Suzhou, February 25, 2025 – Genea Biomedx, part of Basecare Medical Group and a global leader in assisted reproductive technology, has signed a Memorandum of Understanding (MOU) with Rhea Fertility. This strategic collaboration aims to revolutionise fertility treatment by integrating cutting-edge automation and AI-driven solutions to enhance IVF processes worldwide.

The signing ceremony took place at Basecare's headquarters in China, attended by senior executives, including Marian Garriga, CEO of Genea Biomedx, and Margaret Wang, CEO of Rhea Fertility. The agreement strengthens both companies' commitment to advancing laboratory automation and improving patient outcomes through innovative reproductive technologies.

"This collaboration with Rhea Fertility represents an exciting step toward the future of assisted reproduction," said Marian Garriga, CEO of Genea Biomedx. "By combining our expertise in laboratory automation with Rhea's advancements in AI and women's health, we are setting the foundation for smarter, more efficient fertility treatments. Together, we aim to deliver tangible benefits to clinics and patients worldwide."

Margaret Wang, CEO of Rhea Fertility, highlighted the transformative impact of the partnership. "At Rhea Fertility, our mission is to elevate reproductive health journeys for intended parents globally. By integrating AI-driven solutions with Genea Biomedx's world-class automation, we are redefining the IVF process to improve efficiency and clinical outcomes."

The partnership focuses on leveraging Genea Biomedx's advanced technology to optimise workflows in Rhea's IVF laboratories. It will support the development of smart reproductive centres by integrating AI solutions, improving precision, and enhancing lab efficiency. Additionally, the collaboration will facilitate Rhea Fertility's global expansion, particularly in key markets such as the United States, Europe, South America, and Southeast Asia.

As part of the agreement, Rhea Fertility will gain early access to Genea Biomedx's latest products and participate in its Beta Release Program, driving product innovation and accelerating advancements in assisted reproductive technology.

Rhea Fertility, backed by partnerships with NUS Singapore Lab and Baylor College of Medicine, brings expertise in women's health and AI-driven reproductive innovations. This collaboration aims to enhance patient experiences by developing intelligent IVF clinics that deliver more precise and effective treatment options.

The ceremony concluded with both companies reaffirming their shared vision to set new industry benchmarks and drive the future of fertility treatment through technology and innovation.

Genea Biomedx is a leading global provider of advanced medical devices designed to automate and optimise IVF laboratory processes, improving efficiency and clinical outcomes.

Rhea Fertility is a global reproductive health company integrating AI and automation to enhance fertility treatments, with operations in Asia, North America, and Europe.